Home
Browse
Search
Statistics
About
Usage
PMID: 19909502
Kraemer R, Latzin P, Pramana I, Ballinari P, Gallati S, Frey U
Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis.
Respir Res. 2009 Nov 12;10:106.,
[PubMed]
Sentences
No.
Mutations
Sentence
Comment
84
ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 19909502:84:1420
status:
NEW
view ABCC7 p.Arg553* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 19909502:84:1427
status:
NEW
view ABCC7 p.Gly542* details
ABCC7 p.Glu585*
X
ABCC7 p.Glu585* 19909502:84:1444
status:
NEW
view ABCC7 p.Glu585* details
ABCC7 p.Gln525*
X
ABCC7 p.Gln525* 19909502:84:1434
status:
NEW
view ABCC7 p.Gln525* details
According to the frequencies in our Table 1: Patient cohort (A), data base characteristics (B), and distribution of CFTR mutations (C) taken from the Bernese CF Registry (n = 178, 87.3% of a total number of 204 CF patients) A Patient cohort follow-up statistics Gender distribution of patients Blood gas tests within age periods n % - males 88 49.4 5 to 8 y 427/1457 29,3% - females 90 50.6 9 to 14 y 527/1457 36.2% 178 100 15 to 18 y 503/1457 34.5% From entire database, 26 patients (12.7%) excluded because of insufficient number of tests, (6) or age < 6 years (20) B Blood gas test and lung function measurement follow-up statistics Number of blood gas tests median (range) Blood gas tests per year of observation Total of tests 1457 1987 to 1993 326/1457 22.4% per child 8.1 (3-15) 1994 to 2000 539/1457 37.0% per year of observation 68.2 (37-90) 2001 to 2008 592/1457 40.6% C Distribution of CFTR mutations n % Inframe/inframe (F508del[2]) a 103 57.9 Inframe/nonsense b 22 12.4 Frameshift/F508del c 19 10.7 Frameshift/non-F508del d 12 6.7 Inframe/splicesite e 7 3.9 Miscellaneous f 15 8.4 Total 178 100.0 Equal distribution of CFTR genotypes over age range and over years of observation CFTR: cystic fibrosis transmembrane regulator population-specific CFTR genotype distribution, the patients were stratified into 6 groups consisting of (a) F508del homozygotes F508del[2| (inframe/inframe): n = 103 (57.9%), (b)
R553X
,
G542X
,
Q525X
and
E585X
compound heterozygotes with F508del (inframe/nonsense mutations): n = 22, (12.4%), (c) 3905insT compound heterozygotes 3905insT/F508del (frameshift/F508del): n = 19, (10.7%), (d) 3905insT compound heterozygotes with other than F508del (frameshift/non-F508del): n = 12, (6.7%), (e) 1717-1G>A, 621+1G<T and 4005+1G>A compound heterozygotes with F508del (inframe/splicesite): n = 7 (3.9%), and (f) miscellaneous genotypes n = 15, (8.4%).
Login to comment
103
ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 19909502:103:90
status:
NEW
view ABCC7 p.Arg553* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 19909502:103:106
status:
NEW
view ABCC7 p.Gly542* details
frequent CFTR genotypes inframe/inframe (F508del[2]), inframe/nonsense mutations (F508del/
R553X
, F508del/
G542X
, F508del/Q524, F508del/E553), inframe/ frameshift (mainly F508del/3905insT), non-F508del/ frameshift, (mainly non-F508del/3905insT) and inframe/ splicesite genotypes were incorporated as fixed effects with "age at time of annual test" as covariate, and the patient-specific intercept as a random effect.
Login to comment
140
ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 19909502:140:143
status:
NEW
view ABCC7 p.Arg553* details
The so called "Swiss-Type" (3905insT/ F508del), presented with the worst PaO2 values already detectable at the age of 5 years and the subgroup
R553X
/ F508del showed the worst deterioration (steepest slope) over the age range studied.
Login to comment